{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:56:57Z","timestamp":1787237817227,"version":"build-2736575974"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["STRATEGMED3\/306306\/4\/2016"],"award-info":[{"award-number":["STRATEGMED3\/306306\/4\/2016"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["IH R01 NS056872"],"award-info":[{"award-number":["IH R01 NS056872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.neuropharm.2019.107908","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T02:22:30Z","timestamp":1575598950000},"page":"107908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Modifying genetic epilepsies \u2013 Results from studies on tuberous sclerosis complex"],"prefix":"10.1016","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3350-6326","authenticated-orcid":false,"given":"Sergiusz","family":"Jozwiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kotulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107908_bib1","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1161\/STROKEAHA.118.024380","article-title":"Antiepileptic drugs to prevent seizures after spontaneous intracerebral hemorrhage","volume":"50","author":"Angriman","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.neuropharm.2019.107908_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/epi.13782","article-title":"Prospective clinical trials to investigate clinical and molecular biomarkers","author":"Auvin","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/02688697.2018.1464118","article-title":"A systematic review of levetiracetam versus phenytoin in the prevention of late post-traumatic seizures and survey of UK neurosurgical prescribing practice of antiepileptic medication in acute traumatic brain injury","author":"Bakr","year":"2018","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.neuropharm.2019.107908_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2018.03.001","article-title":"Early predictors of clinical and mental outcome in tuberous sclerosis complex: a prospective study","author":"Benova","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinph.2018.03.010","article-title":"Visual and semi-automatic non-invasive detection of interictal fast ripples: a potential biomarker of epilepsy in children with tuberous sclerosis complex","author":"Bernardo","year":"2018","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2007.01458.x","article-title":"Early treatment suppresses the development of spike-wave epilepsy in a rat model","author":"Blumenfeld","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/WCO.0000000000000432","article-title":"New insights into the mechanisms of the ketogenic diet","volume":"30","author":"Boison","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/ajmg.c.31652","article-title":"Current concepts on epilepsy management in tuberous sclerosis complex","author":"Canevini","year":"2018","journal-title":"Am. J. Med. Genet. Part C Semin. Med. Genet."},{"key":"10.1016\/j.neuropharm.2019.107908_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2017.02.007","article-title":"Influence of seizures on early development in tuberous sclerosis complex","author":"Capal","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2019.107908_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2011.08.024","article-title":"Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin","author":"Carson","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.107908_bib11","series-title":"2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society","first-page":"5162","article-title":"Channel selection for epilepsy seizure prediction method based on machine learning","author":"Chang","year":"2012"},{"key":"10.1016\/j.neuropharm.2019.107908_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/ana.23549","article-title":"Changes in interictal spike features precede the onset of temporal lobe epilepsy","volume":"71","author":"Chauvi\u00e8re","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pediatrneurol.2017.05.014","article-title":"Early detection of tuberous sclerosis complex: an opportunity for improved neurodevelopmental outcome","author":"Chung","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2015.12.005","article-title":"Early onset epileptic encephalopathy or genetically determined encephalopathy with early onset epilepsy? Lessons learned from TSC","author":"Curatolo","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib16","series-title":"The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-Based and Expert Opinions. Drugs","author":"Curatolo","year":"2016"},{"key":"10.1016\/j.neuropharm.2019.107908_bib17","series-title":"Handbook of Clinical Neurology","first-page":"323","article-title":"Tuberous sclerosis","author":"Curatolo","year":"2013"},{"key":"10.1016\/j.neuropharm.2019.107908_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2018.05.006","article-title":"Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations","author":"Curatolo","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0387-7604(01)00300-X","article-title":"Infantile spasms in tuberous sclerosis complex","volume":"23","author":"Curatolo","year":"2001","journal-title":"Brain Dev."},{"key":"10.1016\/j.neuropharm.2019.107908_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2011.08.037","article-title":"Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis","author":"Cusmai","year":"2011","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2019.107908_bib21","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4040","article-title":"Presentation and diagnosis of tuberous sclerosis complex in infants","volume":"140","author":"Davis","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.neuropharm.2019.107908_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejpn.2013.12.006","article-title":"EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients \u2013 a prospective study of 5 patients","volume":"18","author":"Doma\u0144ska-Pakie\u0142a","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib24","doi-asserted-by":"crossref","DOI":"10.2147\/BTT.S25095","article-title":"Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex","author":"Franz","year":"2013","journal-title":"Biol. Targets & Ther."},{"key":"10.1016\/j.neuropharm.2019.107908_bib25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","article-title":"Everolimus for treatment-refractory seizures in TSC","volume":"8","author":"Franz","year":"2018","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2019.107908_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","author":"French","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107908_bib27","doi-asserted-by":"crossref","first-page":"E1070","DOI":"10.1073\/pnas.1106454108","article-title":"Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex","volume":"108","author":"Goto","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.107908_bib28","series-title":"Epilepsy and Other Chronic Convulsive Diseases\u00a0: Their Causes, Symptoms and Treatment","author":"Gowers","year":"1881"},{"key":"10.1016\/j.neuropharm.2019.107908_bib29","first-page":"43","article-title":"Expression of tuberin and hamartin in tuberous sclerosis complex-associated and sporadic cortical dysplasia of Taylor's balloon cell type","volume":"46","author":"Grajkowska","year":"2008","journal-title":"Folia Neuropathol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib30","first-page":"CD007286","article-title":"Antiepileptic drugs as prophylaxis for postcraniotomy seizures","volume":"5","author":"Greenhalgh","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.107908_bib31","article-title":"Rapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injury","volume":"8","author":"Guo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.107908_bib32","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.neuropharm.2019.107908_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2018.09.016","article-title":"High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex","author":"Hussain","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2019.107908_bib34","doi-asserted-by":"crossref","DOI":"10.1146\/annurev-pathol-052016-100138","article-title":"Focal cortical dysplasia: gene mutations, cell signaling, and therapeutic implications","author":"Iffland","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2007.01117.x","article-title":"Epilepsy surgery in tuberous sclerosis: a systematic review","author":"Jansen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib36","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.pediatrneurol.2014.08.019","article-title":"Prevention of epileptogenesis\u2014a new goal for epilepsy therapy","volume":"51","author":"J\u00f3\u017awiak","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2016.01.027","article-title":"Safety of everolimus in patients younger than 3 Years of age: results from EXIST-1, a randomized, controlled clinical trial","volume":"172","author":"J\u00f3\u017awiak","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.neuropharm.2019.107908_bib38","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejpn.2011.03.010","article-title":"Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex","volume":"15","author":"J\u00f3\u017awiak","year":"2011","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib39","article-title":"Preventive antiepileptic treatment in tuberous sclerosis complex: long-term, prospective trial","author":"J\u00f3\u017awiak","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2010.02892.x","article-title":"Cerebral tuber count and its impact on mental outcome of patients with tuberous sclerosis complex","author":"Kaczorowska","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","author":"Kotulska","year":"2013","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib42","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ejpn.2014.06.009","article-title":"Epilepsy in newborns with tuberous sclerosis complex","volume":"18","author":"Kotulska","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpn.2018.06.007","article-title":"Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): multicentre clinical experience","author":"Krueger","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib44","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.107908_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","author":"Krueger","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib46","article-title":"Phenytoin versus levetiracetam as prophylaxis for postcraniotomy seizure in patients with no history of seizures: systematic review and meta-analysis","volume":"1\u20138","author":"Lee","year":"2018","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.neuropharm.2019.107908_bib47","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.neuron.2014.09.034","article-title":"The neurology of mTOR","volume":"84","author":"Lipton","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.107908_bib48","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.002386","article-title":"Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia","author":"Ljungberg","year":"2009","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.neuropharm.2019.107908_bib49","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1528-1157.1983.tb04874.x","article-title":"A prospective study of infantile spasms: clinical and therapeutic correlations","volume":"24","author":"Lombroso","year":"1983","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib50","doi-asserted-by":"crossref","DOI":"10.3171\/2012.8.PEDS1285","article-title":"Electrocorticographic evidence of perituberal cortex epileptogenicity in tuberous sclerosis complex","author":"Ma","year":"2012","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.neuropharm.2019.107908_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2011.03.010","article-title":"Human clinical trails in antiepileptogenesis","author":"Mani","year":"2011","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2019.107908_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2011.02981.x","article-title":"The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway","volume":"52","author":"McDaniel","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib53","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and akt signaling lead to improved survival and function","author":"Meikle","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107908_bib54","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.5540-06.2007","article-title":"A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival","author":"Meikle","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107908_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/epi4.12286","article-title":"Epilepsy in tuberous sclerosis complex: findings from the TOSCA Study","volume":"4","author":"Nabbout","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neuropharm.2019.107908_bib56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex Consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurol.2018.11.002","article-title":"Resective surgery in tuberous Sclerosis complex, from Penfield to 2018: a critical review","author":"Ostrowsky-Coste","year":"2019","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.neuropharm.2019.107908_bib58","doi-asserted-by":"crossref","DOI":"10.1111\/epi.13050","article-title":"Epilepsy in Children with Tuberous Sclerosis Complex: Chance of Remission and Response to Antiepileptic Drugs","author":"Overwater","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib59","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14581\/jer.17008","article-title":"Ketogenic diet for the management of epilepsy associated with tuberous sclerosis complex in children","volume":"7","author":"Park","year":"2017","journal-title":"J. Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2019.107908_bib60","article-title":"Significance of tuber size for complications of tuberous sclerosis complex","author":"Pascual-Castroviejo","year":"2013","journal-title":"Neurol. Now."},{"key":"10.1016\/j.neuropharm.2019.107908_bib61","author":"Pinto"},{"key":"10.1016\/j.neuropharm.2019.107908_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.05.007","article-title":"Epilepsy biomarkers \u2013 toward etiology and pathology specificity","author":"Pitk\u00e4nen","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2019.107908_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-014-0257-2","article-title":"Past and present definitions of epileptogenesis and its biomarkers","author":"Pitk\u00e4nen","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2019.107908_bib64","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.pharep.2014.12.017","article-title":"Role of mTOR inhibitors in epilepsy treatment","volume":"67","author":"Sadowski","year":"2015","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2019.107908_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharep.2016.01.005","article-title":"Management of side effects of mTOR inhibitors in tuberous sclerosis patients","author":"Sadowski","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2019.107908_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2019.107908_bib67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13023-018-0764-z","article-title":"Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?","volume":"13","author":"S\u0142owi\u0144ska","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.neuropharm.2019.107908_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2018.06.011","article-title":"Epilepsy treatment patterns among patients with tuberous sclerosis complex","author":"Song","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107908_bib69","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2008.01493.x","article-title":"Tuberous sclerosis: a primary pathology of astrocytes?","author":"Sosunov","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib70","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0883073811413129","article-title":"Treatment of infantile spasms: emerging insights from clinical and basic science perspectives","volume":"26","author":"Stafstrom","year":"2011","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035885","article-title":"The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway","volume":"7","author":"Talos","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.107908_bib72","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1167.2008.02005.x","article-title":"Preventing and treating posttraumatic seizures: the human experience","author":"Temkin","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib73","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1528-1157.2001.28900.x","article-title":"Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials","volume":"42","author":"Temkin","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/ana.10283","article-title":"Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures","author":"Uhlmann","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/0883073818768309","article-title":"Vigabatrin for epileptic spasms and tonic seizures in tuberous sclerosis complex","author":"van der Poest Clement","year":"2018","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib76","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-0136","article-title":"Effect of treatment of subclinical neonatal seizures detected with aEEG: randomized, controlled trial","author":"van Rooij","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.neuropharm.2019.107908_bib77","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/seiz.2001.0629","article-title":"Prophylactic antiepileptic treatment in Sturge\u2013Weber disease","volume":"11","author":"Ville","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2019.107908_bib78","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0387-7604(87)80111-0","article-title":"Identification of infants at risk for infantile spasms by neonatal polygraphy","volume":"9","author":"Walther","year":"1987","journal-title":"Brain Dev."},{"key":"10.1016\/j.neuropharm.2019.107908_bib79","series-title":"The Effectiveness of Antiepileptic Medications as Prophylaxis of Early Seizure in Patients with Traumatic Brain Injury Compared with Placebo or No Treatment: A Systematic Review and Meta-Analysis","author":"Wat","year":"2019"},{"key":"10.1016\/j.neuropharm.2019.107908_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/155005948301400205","article-title":"The prognostic value of EEG in neonatal meningitis","volume":"14","author":"Watanabe","year":"1983","journal-title":"Clin. Electroencephalogr."},{"key":"10.1016\/j.neuropharm.2019.107908_bib81","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0387-7604(87)80112-2","article-title":"Neurophysiological and neuroradiological features preceding infantile spasms","volume":"9","author":"Watanabe","year":"1987","journal-title":"Brain Dev."},{"key":"10.1016\/j.neuropharm.2019.107908_bib82","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pediatrneurol.2017.04.009","article-title":"The utility of surveillance electroencephalography to guide early antiepileptic drug therapy in infants with tuberous sclerosis complex","volume":"72","author":"Whitney","year":"2017","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2011.10.002","article-title":"Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations","author":"Wong","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/epi.16379","article-title":"Scalp EEG spikes predict impending epilepsy in TSC infants: a longitudinal observational study","author":"Wu","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107908_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.pediatrneurol.2015.09.013","article-title":"Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants","author":"Wu","year":"2016","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib86","author":"Yan"},{"key":"10.1016\/j.neuropharm.2019.107908_bib87","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-010-0677-y","article-title":"Balloon cells in human cortical dysplasia and tuberous sclerosis: isolation of a pathological progenitor-like cell","author":"Yasin","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib88","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1523\/JNEUROSCI.0066-09.2009","article-title":"The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy","volume":"29","author":"Zeng","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107908_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","author":"Zeng","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107908_bib90","article-title":"Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2019.107908_bib91","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nbd.2015.04.016","article-title":"Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex","volume":"80","author":"Zhang","year":"2015","journal-title":"Neurobiol. Dis."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819304794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819304794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:55:58Z","timestamp":1762214158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819304794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":91,"alternative-id":["S0028390819304794"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107908","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modifying genetic epilepsies \u2013 Results from studies on tuberous sclerosis complex","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107908"}}